Company Overview and News
This copy is for your personal non-commercial use only. To order presentation-ready copies of Toronto Star content for distribution to colleagues, clients or customers, or inquire about permissions/licensing, please go to: www.TorontoStarReprints.com
WOPEF TRP RDS.B RDS.A XOM RDSB RDSA WPL WOPEY TOU ATGFF CNQ CVX RYDBF TRMLF RYDAF ALA
(Bloomberg) -- While the LNG Canada facility that was greenlighted Tuesday won’t be operating for years, the battered Canadian energy industry is already hoping that it will be the first of many such plants on the country’s Pacific Coast.
WOPEF TRP XOM WPL WOPEY TOU ATGFF CNQ CVX TRMLF ALA
Monthly paying (MoPay) dividend equities make dividend payouts to shareholders twelve times a year instead once, twice, or four times.
MGRUF FFN NAF.UN CRIUF MHIVF ATGFF RNW SOT.UN EFRTF AHOTF DR.DB.A DVVDF TRSWF ARESF DR CNDCF KWH.UN BK MFCSF FNCSF ALA
AltaGas (OTCPK:ATGFF) has been a stock that we have been rather negative on. Don't believe us? Just look at our resume on the subject.
October's U.S. Exchange monthly-paid dividends; upsides; net gains: 1. Stocks by yield >0.5% (87); 2. Stocks by price upside (30); 3. Closed-End Investment Companies, Exchange-Traded Funds and Notes (CEICs/ETFs/ETNs) by yield (80).
SCA CLA GOOD GECC HRZN HTF ORC OXLCO ROYT OXLCN MORL SCM GOODM ATGFF GOODN THO ECC LMLP HTFA ECCZ DVHL AGNC CPTA ECCY GOODO GOODP TAHO CEFL HCAPL OXLC ECCB SCQ ECCA HCAP SUNS PVL GNL ALA
NEW YORK, Sept 25 (Reuters) - * The Toronto Stock Exchange’s S&P/TSX fell 47.82 points, or 0.3 percent, to 16,159.50. * Leading the index were Ivanhoe Mines Ltd, up 7.0 percent, Aurora Cannabis Inc, up 4.1 percent, and Kirkland Lake Gold Ltd , higher by 4 percent. * Lagging shares were Martinrea International Inc, down 4.9 percent, Magna International Inc, down 4.7 percent, and AltaGas Ltd, lower by 3.
MRETF KGI KGI.DB.A ACBFF KGI.DB IVN IVPAF ACB ATGFF MGA APH MRE MG BTE APHQF ALA KL
SECURITIES AND EXCHANGE COMMISSION
2018-09-23 seekingalpha - 1
Our negative AltaGas (OTCPK:ATGFF) articles have not been well received. We have been accused of trying to manipulate the stock lower (we have zero influence), being short (we aren't), or being clueless about how utilities work (we have at least one clue). Since our initial bear call, the stock is down about 25%. Of course, price action can go horribly away from fundamentals, something we as value investors are acutely aware of.
AltaGas has been consistently investing in U.S. projects over Canadian ones. Recent divestitures to fund the U.S. based WGL Holdings acquisition have tilted Canadian.
SOJA DUKH SO TRP SCG WGL DTK DUK ENB ENB ATGFF EQT WMB TRP ED PBA
2018-09-17 seekingalpha - 2
AltaGas Ltd. [TSX:ALA](OTCPK:ATGFF) used a mix of debt and essentially stock for the ~CAD$9 billion WGL Holdings acquisition. The debt included a ~US$4.95 billion bridge facility. It also raised capital from the markets by selling CAD$2.6 billion of subscription receipts in Q1 2017.
TWMIF ATGFF WGL ALA
It's your September 2018 Monthly-Paid (MoPay) Small-Mid-Large Cap Dividend, Yield, Upsides, and Net Gains Report. Nano-Cap MoPays <$200M are not listed.
CRLFF CRIUF ORC MHIVF GLADO ATGFF AGNC TRSWF KWH.UN PSEC SCQ PBB MGRUF SCA CJ GOOD OXLCO OXLCN SCM GOODM GLAD SOT.UN RNW GOODN ECC ECCZ AHOTF ECCY GOODO GOODP SRRTF ARESF CGIFF PZRIF ?NHF? OXLC ECCB ARR ECCA SUNS GNL NHF ALA SRT.UN PZA
2018-10-01 - Asif
Overview The following discussion and analysis should be read in conjunction with its unaudited interim condensed consolidated financial statements and the related notes that appear elsewhere in this quarterly report on Form 10-Q. This discussion contains forward-looking statements reflecting its current expectations that involve risks and uncertainties. Actual results may differ materially from those discussed in these forward-looking statements due to a number of factors, including those set forth in the section entitled “Risk Factors” in its most recent annual report on Form 10-K. For further information regarding forward-looking statements, please refer to the “Special Note Regarding Forward-Looking Statements and Projections” immediately after the index to this quarterly report on Form 10-Q. Alimera Sciences, Inc., and its subsidiaries (we or Alimera), is a pharmaceutical company that specializes in the commercialization and development of prescription ophthalmic pharma...
2018-09-25 - Asif
Background DelMar Pharmaceuticals, Inc. is a clinical stage drug development company with a focus on the treatment of cancer. The company's mission is to benefit patients and create shareholder value by developing and commercializing anti-cancer therapies for patients whose tumors exhibit features that make them resistant to, or unlikely to respond to, currently available therapies, particularly for orphan cancer indications where patients have failed, or are unlikely to respond to, currently available therapy. DelMar Pharmaceuticals is developing VAL-083, a novel, DNA-targeting agent, for the treatment of glioblastoma multiforme (“GBM”) and potentially other solid tumors, including ovarian cancer. VAL-083 is a first-in-class, DNA-targeting chemotherapeutic that demonstrated activity against a range of tumor types in prior Phase 1 and Phase 2 clinical studies sponsored by the US National Cancer Institute (“NCI”). The company's recent research has highlighted the opportunit...
2018-09-18 - Asif
Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...